Drugs / TMB-365
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04027387 | Dec 2019 → Aug 2021 | HIV infectious disease | TaiMed Biologics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05275998 | Jul 2022 → Nov 2024 | HIV infectious disease | TaiMed Biologics Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07215468 | Dec 2025 → Aug 2027 expected | HIV infectious disease | TaiMed Biologics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMB-365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215468 ↗ |
| Action | Inhibit | “A monoclonal antibody acts as a HIV post-attachment inhibitor” NCT07215468 ↗ |
| Modality | Monoclonal antibody | “An IgG1 monoclonal antibody” NCT04027387 ↗ |
| Route | Intravenous | “administered via intravenous infusion (IV)” NCT04027387 ↗ |
| Target | CD4 | “targeting domain 2 of the CD4 receptor” NCT04027387 ↗ |